Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
305 results
100093 - Arcoxia - cause of erythema fixed drug
100147 - Flare up by diethylthiurea/dibutylthiourea
100166 - Contact urticaria with phenoxyethanol
100209 - Reliability of UCT and DLQI Questionnaires for Urticaria in the Republic of Kazakhstan
100541 - Systematic evaluation of ChatGPT`s performance on 40 dermatological allergology questions with clinical error impact assessment for erroneous AI-guided chatbot-advice
D1.20 - Progesterone-Induced Urticaria: Diagnostic and Therapeutic Approach
D1.25 - Clinical Characteristics of Chronic Urticaria in Adults Under 45 Years Old with Vitamin D Insufficiency
D1.372 - Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria
D1.375 - Ciclosporin for omalizumab-refractory CSU in a Paediatric population in Cork University Hospital: a case series
D1.376 - Emerging inmunomodulatory agents for atopic dermatitis
D1.377 - Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report
D1.378 - Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis
D1.384 - Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective “Real-Life” Analysis
D1.385 - Dupilumab Treatment Effects on Atopic Manifestations in Patients with Inborn Errors of Immunity
D2.294 - Allergic contact dermatitis unit at Hospital Joan XXIII (Tarragona, Spain): descriptive analysis 2022 - 2023
D2.295 - Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters
D2.296 - Allergic contact dermatitis caused by a oxybutynin in a transdermal patch
D2.297 - SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria
D2.299 - A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway
D2.300 - Fixed Drug Eruption related to the use of NSAIDs
Pagination
First page
First
Previous page
Previous
…
Page
7
Page
8
Page
9
Page
10
Current page
11
Page
12
Page
13
Page
14
Page
15
…
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download